|
|
News Breaks | | | | February 4, 2013 | | 08:32 EDT |  | GILD | Gilead announces results from FISSION, NEUTRINO Phase 3 studies
Gilead Sciences announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin and in combination with ribavirin and pegylated interferon among treatment-naïve patients with chronic HCV infection. In the FISSION study, patients with genotype 2 or 3 HCV infection were randomized to receive either a 12-week course of sofosbuvir plus ribavirin or standard of care with 24 weeks of pegylated interferon alfa-2a plus RBV. The study met its primary efficacy endpoint of non-inferiority of sofosbuvir plus RBV to peg-IFN plus RBV, with 67% of patients achieving a sustained virologic response in the sofosbuvir plus RBV treatment group versus 67% in the peg-IFN plus RBV treatment group. In the NEUTRINO study, patients with genotype 1, 4, 5 or 6 HCV infection were treated with a 12-week course of sofosbuvir, RBV and peg-IFN. This study met its primary efficacy endpoint of superiority compared to a predefined historic control SVR rate of 60% with 90% of patients achieving SVR12 after completing therapy. | |
|
News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. |
|
|
| May 16, 2013 | | 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
 Subscribe for More Information | | | May 15, 2013 | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | May 13, 2013 | | 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR | |
|
|
|
|
|
|
